Lantheus — Third Quarter 2026 Earnings Summary

Lantheus Holdings reported third-quarter 2026 worldwide revenue of $389.9 million, representing a 1.5% increase from the prior year period. The company achieved GAAP fully diluted earnings per share of $0.33 and adjusted fully diluted earnings per share of $1.68. Regulatory milestones included FDA approval for the tau PET imaging agent TAUKLARIFY and final approval for BRAVNETSA, a bioequivalent alternative to LUTATHERA. Additionally, Lantheus announced a definitive agreement to merge with Curium in an all-cash transaction valued at up to $8.0 billion, leading to the suspension of its full-year 2026 financial guidance.